Emeramide: Features of a unique chelator
EmeraMed Ltd is a biotechnology company developing Emeramide (N,N′-bis(2-mercaptoethyl)isophthalamide), a lipophilic compound that crosses the blood-brain barrier and is intracellularly accessible.Emeramide is under FDA review as a treatment for mercury poisoning. In preclinical studies, Emeramide has demonstrated the ability to chelate mercury.
Emeramide: A History of Success
Emeramide was first introduced in 2008 as OSR#1®. Approximately 2.5 million doses of the compound were distributed. Clinical studies have been conducted, including Phase 1 and Phase 2 trials.
Properties
Emeramide is lipophilic, meaning it is soluble in fatty tissues. Laboratory experiments have examined the formation of complexes with certain metals. The resulting complexes have been studied for characteristics such as solubility in fat, water, acid, or base, as well as thermal stability.
Emeramide: Safety Observations
Safety studies in multiple animal species showed no evidence of toxicity at the doses tested. In human studies involving administration for up to 30 days at 300 mg per day and 10 days at 600 mg per day, no adverse events were reported and no depletion of essential minerals was observed in the published data. Additional studies in animals given the preformed metal complex reported no evidence of harm.
Legal Disclaimer
This page provides general information about the chemical composition and development history of Emeramide. Emeramide has not been approved by the U.S. Food and Drug Administration (FDA) for any purpose. The information on this website has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Emeramide is an investigational compound. It is not available for general use. Any potential use of this compound must be conducted in full compliance with all applicable federal, state, and local laws and regulations.